What EPIDAREX EXEED LIMITED does

Epidarex Exeed Limited is a Scottish-incorporated therapeutic discovery engine established in December 2019 by Epidarex Capital as a wholly-owned subsidiary vehicle for seeding and de-risking early-stage life science assets. The company sources breakthrough science from academic research institutions and pairs it with drug discovery, project management, and CRO partners to advance assets over a defined 12-18 month window into investable, Series-A-ready spin-out companies. Its core product is the discovery engine process itself rather than a discrete therapeutic, and its first realized output is Lario Therapeutics (founded November 2021), a biopharmaceutical spin-out developing first-in-class CaV2.3 ion channel inhibitors for CDKL5 Deficiency Disorder and treatment-resistant epilepsies.

The business model is venture-style rather than product-sales oriented: revenue is generated through equity ownership, licensing/royalty arrangements, and the future successful exit of portfolio companies created via the discovery engine. The primary customer segments are academic research institutions/universities with breakthrough science, and the resulting life science spin-out companies that are then positioned for Series A investment under Epidarex Capital's lead. Distribution is conducted through direct outreach, the corporate website, an email newsletter, and participation in relevant scientific forums (e.g., the CDKL5 Forum). The company is GDPR-compliant, headquartered at 137a George Street, Edinburgh, and operates with a deliberately lean core team of approximately five professionals, supplemented by external CRO and drug discovery partners.

Leadership is concentrated among senior pharma and venture capital operators: CEO and co-founder Dr. Henning Steinhagen (former President R&D at Aptuit, SVP/Head of Global Drug Discovery at Grünenthal, with senior roles at Sanofi-Aventis and Bayer Pharma); Chair and co-founder Dr. Liz Roper (Partner at Epidarex with prior roles at Chroma Therapeutics, Wellcome Trust, and Atlas Ventures); Director Dr. Pete Finan (former Global Head of Respiratory Disease Area and Site Head at Novartis Institute of BioMedical Research UK); Operations and Project Management Daniel Gill (ex-Wellcome Trust Innovations and Locate Therapeutics); and Consultant Head of Finance Richard Brooks (co-founder of FD Solutions).

Name

EPIDAREX EXEED LIMITED

Legal name

Epidarex Exeed Limited

Website

https://epidarex-exeed.com

Company type

Private

Founded year

2019

Operating status

Operating

Short description

Epidarex Exeed is a Scottish therapeutic discovery engine, founded in 2019 by Epidarex Capital, that sources early-stage academic life science assets, de-risks them over 12-18 months with drug discovery and CRO partners, and creates investable spin-out companies ready for Series A funding.

Ownership category

akta.pro rank

Product category

Biotechnology Venture Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Therapeutic discovery engine
• Early stage life sciences
• Drug discovery seeding
• Biotech venture creation
• Spin-out company formation

Headquarters

HQ city

Edinburgh

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Venture Capital / Investment Returns: Epidarex Exeed seeds early stage highly innovative life science assets and creates companies ready for Series A investment. Revenue is generated through successful exit of portfolio companies and investment returns from seed funding provided by Epidarex Capital.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Epidarex Exeed is a therapeutic discovery engine that identifies innovative early-stage life science assets, typically from leading academic research institutions, and applies drug discovery and project management capabilities to transform them into investable companies over a 12-18 month period. The company provides hands-on scientific support, project management and seed funding, then creates new spin-out companies positioned for Series A investment under the leadership of Epidarex Capital.

Product overview

Epidarex Exeed is a therapeutic discovery engine backed by Epidarex Capital with the mission to seed and advance early stage and highly innovative life science assets to create investable companies based on breakthrough science. The company pairs world-class science with leading drug discovery, project management, and CRO partners to advance early stage assets over 12-18 months, with the goal of creating new companies under the leadership of Epidarex Capital. Its portfolio includes its core therapeutic discovery engine and its first spin-out company, Lario Therapeutics, which focuses on developing precision medicines for severe neurological disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Epidarex Exeed Therapeutic Discovery Engine A therapeutic discovery engine that identifies innovative early-stage life science assets from academic research institutions, applying drug discovery and project management capabilities over a 12-18 month period to transform them into investable spin-out companies ready for Series A funding. Targeted at academic researchers and institutions with breakthrough therapeutic opportunities.
• Lario Therapeutics A biopharmaceutical spin-out company from Epidarex Exeed developing first-in-class, orally active, CNS-penetrant CaV2.3 ion channel inhibitors as precision medicines targeting disease-modifying treatments for severe neurological disorders, including CDKL5 Deficiency Disorder and multiple treatment-resistant epilepsy subtypes. Aimed at patients with severe genetic epilepsies and treatment-resistant seizure disorders.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Lario TherapeuticscoreStrategic or Co-development Partner · 1 November 2021Lario Therapeutics is the first spin-out company from Epidarex Exeed, founded in November 2021. It is a biopharmaceutical company developing first-in-class precision medicines for severe neurological disorders including CDKL5 Deficiency Disorder. Epidarex Exeed provided the discovery engine that advanced the asset to spin-out stage.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Atlas Venture: Early-stage biotech VC that systematically creates and builds new companies from academic and industry sources, often providing hands-on operational support; comparable in its company-creation engine model and team-based approach.
• BioMotiv: US-based therapeutic accelerator that curates and advances breakthrough academic science into investable biotech opportunities, with a similar mission of bridging the early-stage funding gap between basic research and traditional VC.
• Harrington Discovery Institute: Academic-to-clinic therapeutic accelerator that funds and advances breakthrough discoveries into investable development programs; comparable mission of bridging academic science to company formation with experienced drug discovery oversight.
• Apollo Therapeutics: UK-based therapeutic venture studio co-founded by AstraZeneca, GSK, Johnson & Johnson and Imperial College London that funds and accelerates academic life science assets toward investable companies. Highly comparable structure to Epidarex Exeed's CRO-orchestrated, pharma-experienced discovery engine model.
• RTW Investments: Biotech-focused investment firm that takes concentrated positions in early-stage therapeutic programs and supports company formation; comparable in its specialization on early-stage life science opportunities and willingness to back pre-clinical assets.
• SV Health Investors: Specialist healthcare and biotech VC firm with deep pharma operator networks that invests in early-stage therapeutic opportunities; comparable as a specialized life science investor with operator-style support for portfolio companies.
• Bridge Medicines: Drug-discovery incubator founded with pharma backing (Bayer, BMS, Takeda) that advances academic therapeutic programs through a structured, partnered model; directly comparable to Epidarex Exeed's role as an externally-funded discovery engine.
• Medicxi Ventures: Europe-based, asset-centric biotech investment firm that backs single therapeutic programs and spins out companies around them; comparable in its focus on early-stage therapeutic assets and creation of dedicated companies around validated science.

Broad incumbents

• Evotec: Integrated drug discovery company with a venture-creation arm (e.g., BRIDGE model) that co-founds biotechs around its platform programs; comparable as a larger, established player that creates multiple therapeutic companies from internal discovery work.

Others

• Cleveland Clinic Therapeutics: Large academic medical center with internal therapeutic accelerator programs that spin out companies from institutional science; relevant adjacent ecosystem participant with a comparable academic-to-company model but different geographic and institutional context.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EPIDAREX EXEED LIMITED